Next Article in Journal
New Benzoyl Glucosides and Cytotoxic Pterosin Sesquiterpenes from Pteris ensiformis Burm.
Next Article in Special Issue
Synthesis and Properties of a New Water-Soluble Prodrug of the Adenosine A2A Receptor Antagonist MSX-2
Previous Article in Journal
Isolation and Identification of an Anti-tumor Component from Leaves of Impatiens balsamina
Previous Article in Special Issue
Trimethyl Lock: A Stable Chromogenic Substrate for Esterases
Molecules 2008, 13(2), 230-254; doi:10.3390/molecules13020230
Review

Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug

1,* , 2, 3, 4 and 1
1 Istituto Auxologico Italiano, IRCCS – Department of Neurology – Ospedale S. Giuseppe, Piancavallo, PO. Box 1 – 28921 Verbania, Italy 2 University of Torino – Department Anatomy Pharmacology Forensic Medicine – Torino, Italy 3 Istituto Auxologico Italiano, IRCCS – Department of Neurology – Laboratory of Clinical Neurobiology – Verbania, Italy 4 Nanovector S.r.l. – Torino, Italy 5 University of Torino – Departement of Neurosciences – Torino, Italy
* Author to whom correspondence should be addressed.
Received: 4 January 2008 / Revised: 31 January 2008 / Accepted: 1 February 2008 / Published: 1 February 2008
(This article belongs to the Special Issue Prodrugs)
View Full-Text   |   Download PDF [155 KB, uploaded 18 June 2014]   |   Browse Figures
SciFeed

Abstract

Cholesterylbutyrate (Chol-but) was chosen as a prodrug of butyric acid.Butyrate is not often used in vivo because its half-life is very short and therefore too largeamounts of the drug would be necessary for its efficacy. In the last few years butyric acid'santi-inflammatory properties and its inhibitory activity towards histone deacetylases havebeen widely studied, mainly in vitro. Solid Lipid Nanoparticles (SLNs), whose lipid matrixis Chol-but, were prepared to evaluate the delivery system of Chol-but as a prodrug and totest its efficacy in vitro and in vivo. Chol-but SLNs were prepared using the microemulsionmethod; their average diameter is on the order of 100-150 nm and their shape is spherical.The antineoplastic effects of Chol-but SLNs were assessed in vitro on different cancer celllines and in vivo on a rat intracerebral glioma model. The anti-inflammatory activity wasevaluated on adhesion of polymorphonuclear cells to vascular endothelial cells. In thereview we will present data on Chol-but SLNs in vitro and in vivo experiments, discussingthe possible utilisation of nanoparticles for the delivery of prodrugs for neoplastic andchronic inflammatory diseases.
Keywords: Cholesterylbutyrate; Solid Lipid Nanoparticles; Butyric Acid; Cancer; Brain Tumours; Inflammatory Diseases. Cholesterylbutyrate; Solid Lipid Nanoparticles; Butyric Acid; Cancer; Brain Tumours; Inflammatory Diseases.
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Brioschi, A.; Zara, G.P.; Calderoni, S.; Gasco, M.R.; Mauro, A. Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug. Molecules 2008, 13, 230-254.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert